First Brands Group debt targeted by Apollo Global Management - report
ORLANDO - Nutriband Inc. (NASDAQ:NTRB) reported a 50.87% year-over-year revenue increase to $1,289,884 for the six months ended July 31, 2025, according to a company press release issued Wednesday. The growth aligns with the company’s strong momentum, having achieved a 42.92% revenue increase over the last twelve months.
The pharmaceutical company, which specializes in transdermal products, stated it had $6.9 million in cash reserves as of July 31, with total assets of $10.17 million and stockholders’ equity of $8.5 million. With a current ratio of 4.78, InvestingPro data shows the company maintains strong liquidity with liquid assets well exceeding short-term obligations.
Nutriband announced it has been granted a Type C meeting with regulators on September 18 regarding its lead product, AVERSA Fentanyl, an abuse-deterrent transdermal patch. The company noted that the New Drug Application (NDA) for this product will primarily rely on data from a single phase 1 Human Abuse Potential study, with no Phase 2 or 3 clinical trials required before submission.
According to the company, a market analysis report from Health Advances estimates that AVERSA Fentanyl could potentially reach peak annual sales of $80-$200 million if approved. The company claims it would be the first abuse-deterrent transdermal patch available globally. With a current market capitalization of $67.67 million and analysts setting a $15 price target, InvestingPro subscribers can access 8 additional key insights about the company’s growth potential.
Nutriband also reported continued expansion of its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. The company’s stock has shown strong performance, delivering a 57.11% return over the past year despite recent market volatility.
The AVERSA technology is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential when incorporated into transdermal patches, the company stated.
In other recent news, NutriBand Inc. reported that the exercise of stock options and warrants between February 1 and July 31, 2025, resulted in gross proceeds of approximately $5.35 million. The company disclosed that stock options covering 20,055 shares of common stock were exercised for a total of $44,206, while public and private warrants generated additional proceeds. NutriBand also announced a Type C Meeting with the U.S. Food and Drug Administration (FDA) for its AVERSA FENTANYL abuse-deterrent transdermal system, scheduled for September 18, 2025. This meeting will focus on providing feedback on the Chemistry, Manufacturing, and Controls plans for the product. Additionally, NutriBand has declared a preferred stock dividend, with shareholders of record on July 25, 2025, set to receive one preferred share for every four common shares held. The preferred shares are convertible to common shares following FDA approval of the AVERSA Fentanyl product. The company has also authorized a new class of non-voting Series A Convertible Preferred Stock, allowing for the issuance of up to 2,788,678 shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.